Teva set to invest in MediWound:
This article was originally published in Clinica
Israeli wound care company MediWound has attracted funding from several institutional, private and corporate investors including Teva Pharmaceutical Industries, one of the world's largest generic pharmaceutical companies, which is set to invest $15m. Teva will pay $10m for shares from MediWound stockholders and an additional $5m for shares issued by the company itself. The transaction will also see Teva gain exclusive marketing and distribution rights to MediWound's Debrase gel dressing for burns in certain countries, while MediWound will manufacture the product and supply it to Teva for commercialisation. Petach Tikva-based Teva will have an option to extend the licence agreement to include Europe and North America. Debrase, currently in phase III clinical trials, can remove 90% of burnt tissue on a patient within four hours, according to MediWound.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.